These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529 [TBL] [Abstract][Full Text] [Related]
23. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. Sanderson KM; Cai J; Miranda G; Skinner DG; Stein JP J Urol; 2007 Jun; 177(6):2088-94. PubMed ID: 17509294 [TBL] [Abstract][Full Text] [Related]
25. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? Divrik T; Yildirim U; Eroğlu AS; Zorlu F; Ozen H J Urol; 2006 Apr; 175(4):1258-61. PubMed ID: 16515974 [TBL] [Abstract][Full Text] [Related]
26. Outcome of very large superficial bladder tumours: a 10-year experience. Gupta SK; Parr NJ Scand J Urol Nephrol; 2008; 42(3):243-8. PubMed ID: 18432531 [TBL] [Abstract][Full Text] [Related]
27. Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection. Deng N; Chen JX; Chen LW; Qiu SP; Li XF; Wang DH Chin Med J (Engl); 2012 Oct; 125(20):3681-6. PubMed ID: 23075724 [TBL] [Abstract][Full Text] [Related]
28. Upper urinary tract recurrence following radical cystectomy for bladder cancer. Furukawa J; Miyake H; Hara I; Takenaka A; Fujisawa M Int J Urol; 2007 Jun; 14(6):496-9. PubMed ID: 17593092 [TBL] [Abstract][Full Text] [Related]
29. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Li M; Song T; Yin ZF; Na YQ Chin Med J (Engl); 2007 Mar; 120(6):469-73. PubMed ID: 17439739 [TBL] [Abstract][Full Text] [Related]
30. Relook TURBT in superficial bladder cancer: its importance and its correlation with the tumor ploidy. Dwivedi US; Kumar A; Das SK; Trivedi S; Kumar M; Sunder S; Singh PB Urol Oncol; 2009; 27(5):514-9. PubMed ID: 18639472 [TBL] [Abstract][Full Text] [Related]
32. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables. Ather MH; Zaidi M Urol J; 2009; 6(3):189-93. PubMed ID: 19711273 [TBL] [Abstract][Full Text] [Related]
33. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Denzinger S; Burger M; Walter B; Knuechel R; Roessler W; Wieland WF; Filbeck T Urology; 2007 Apr; 69(4):675-9. PubMed ID: 17445650 [TBL] [Abstract][Full Text] [Related]
34. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341 [TBL] [Abstract][Full Text] [Related]
35. [The value of differentiated transurethral resection in primary superficial bladder cancer]. Flamm J; Steiner R Urologe A; 1991 Mar; 30(2):111-3. PubMed ID: 2058065 [TBL] [Abstract][Full Text] [Related]
36. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905 [TBL] [Abstract][Full Text] [Related]